Augustine Madueke

Mr. Augustine Madueke

UNIVERSITY OF NIGERIA, NSUKKA, NIGERIA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Emmanuel OssaiEmmanuel Ossai
Emmanuel Ossai
Augustine MaduekeAugustine Madueke
Augustine Madueke
BABenjamin Emenike Amadi
Benjamin Emenike Amadi
MOMARTINS OGUGOFOR
MARTINS OGUGOFOR
MMMomoh A. Mumuni
Momoh A. Mumuni
ONObioma Uzoma Njoku
Obioma Uzoma Njoku
The potential enhancement of metformin hydrochloride (MH) loaded in lipid vesicles targeting therapeutic efficacy on alloxan-induced diabetic rats was investigated. This involved lipid vesicles formulated with homogenously distributed nano-sized particles by a novel integrated process of multiple emulsification by membrane and solvent evaporation. The average diameter of the water-in-oil (W1/O), W1/O/W2 emulsion droplets, and lipid vesicles was 192 nm, 52 µm, and 173 nm, respectively. The entrapment yield of metformin hydrochloride (MH) in the prepared lipid vesicles was 40.12%. The metformin hydrochloride-loaded lipid vesicles (MH-LLVs) sustained the release of the entrapped drug over a 12-h period and reduced the plasma glucose level of diabetic rats by 77.4% compared with free MH solution (2-h period and 58.2%, respectively) after one week post-diabetic treatment through oral administration of MH-LLV and the free drug. The remarkable improvement in the biochemical parameters recorded in the MH-LLV-treated animals compared with those that received free MH solutions depicted an enhanced kidney function, liver function, as well as oxidative stress status. Pancreatic histology depicted a pancreas with intralobular ducts (ID) and exocrine secretory acini that characterize an intact pancreas, which suggests the ability of the MH-LLVs to restore pancreatic cells to normal, on a continued treatment. Overall, MH-LLV appears an encouraging extended-release formulation with enhanced bioavailability, sustained release, and improved antihyperglycemic potentials.

30 November 2020 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
Augustine MaduekeAugustine Madueke
Augustine Madueke
VNValentine Nwanelo
Valentine Nwanelo
ETEmmanuel Tabansi
Emmanuel Tabansi
AOAmarachukwu Onoh
Amarachukwu Onoh
RARemigus Anichebe
Remigus Anichebe
AAAssumpta Anosike
Assumpta Anosike
Chasmanthera dependens is a medicinal plant with wide application in African traditional medicine for the management of several pathologies. We report the antioxidant properties of the chloroform extract of C. Dependens root (CECDR) as to auspiciously provide scientific information that could explain some of the reported roles of the plant in human diseases. In vitro studies assayed for 1,1-diphenyl2-picrylhydrazyl (DPPH) scavenging, hydrogen peroxide scavenging, ferric reducing antioxidant power (FRAP), and total antioxidant capacity (TAC). DPPH radical scavenging activity was concentration dependent with an EC50 of 647.67 μg/mL. CECDR showed a positive hydrogen peroxide scavenging with EC50 of 57.78 ± 2.93 μg/mL relative to ascorbic acid standard (EC50: 90.06 μg/mL). The ferric reducing antioxidant power of CECDR at 15.6 μg/mL was 21.18 ± 0.15 µg gallic acid equivalents (GAE) while that of 1000 μg/mL was 0.03 ± 0.00 µg GAE. CECDR at a concentration 15.6 μg/mL showed a TAC of 15.22 ± 7.81 µg ascorbic acid equivalents (AAE) while that of 1000 μg/mL was 0.03 ± 0.00 µg AAE. In vivo analysis of CCl4-induced Wistar rats showed a significant increase (p < 0.05) in the concentrations of superoxide dismutase, catalase, and glutathione peroxidase in the treated groups relative to the untreated control. In conclusion the observed antioxidant properties of CECDR could be attributed to its rich phytochemical repertoire.

2 June 2026 in Biophysica
Verified
Journal Article
Open access
PDF file
SEShadrach C Eze
Shadrach C Eze
NSNnemolisa Stephen
Nnemolisa Stephen
JOJoy C. Onyesoro
Joy C. Onyesoro
TIToluwalope Daniel Ilori
Toluwalope Daniel Ilori
VUVictor S. Uche
Victor S. Uche
IOInnocent Okagu
Innocent Okagu
Beta Secretase (BACE1) is a well-validated target for Alzheimer’s therapies, but there has been attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and dynamics were used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307 ± 0.109 Å) compared to Verubecestat (1.602 ± 0.159 Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (−33.820 ± 4.254) had comparatively lower energy than Verubecestat (−21.090 ± 6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 and Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrates the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.

23 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SEShadrach C Eze
Shadrach C Eze
NSNnemolisa Stephen
Nnemolisa Stephen
JOJoy C. Onyesoro
Joy C. Onyesoro
TIToluwalope Daniel Ilori
Toluwalope Daniel Ilori
VUVictor S. Uche
Victor S. Uche
IOInnocent Okagu
Innocent Okagu
Beta Secretase (BACE-1) is a well-validated target for Alzheimer’s therapies, but have seen attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and MD (250ns) was used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for the BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307±0.109 Å) compared to Verubecestat (1.602±0.159Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (-33.820±4.254) had comparatively lower energy than Verubecestat (-21.090±6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 & Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrate the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.

30 September 2021 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
ICIfeoma Chukwuma
Ifeoma Chukwuma
VAVictor Onukwube Apeh
Victor Onukwube Apeh
FNFlorence Nkechi Nworah
Florence Nkechi Nworah
Augustine MaduekeAugustine Madueke
Augustine Madueke
VNValentine Nwanelo
Valentine Nwanelo
The re-emergence of severe acute respiratory syndrome coronavirus 2 A(SARS-CoV-2) in Wuhan, China, has placed an unprecedented economic and health burden globally. The SARS-CoV-2 high mortality rate has brought great challenges to researchers, clinicians, and health workers in their bid to discover appropriate therapeutic interventions. The search for the ultimate remedy was initially centered on the use of antiviral agents targeting receptors and proteins involved in the pathophysiology of SARS-CoV-2. However, the upsurge of interest in repurposing anti-inflammatory agents was born out of the reported risks posed by a cytokine storm on COVID-19-induced fatality. A cytokine storm, as a result of the unregulated production of pro-inflammatory cytokines and other chemical mediators, triggers coagulopathy, viral sepsis, pneumonitis shock, and acute respiratory syndrome, which may lead directly to respiratory and organ failure and ultimately the death of the patient. The overwhelming evidence has shown that the early prediction of cytokine storm using serum chemistry and hematological markers and the use of appropriate anti-inflammatory agents will avert COVID-19 complications. These include the use of repurposed interferon (IFN) therapy and inhibitors of interleukin-1 (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and Janus kinase (JAKs) to nip the cytokine storm in the bud. This review critically used information retrieved from PubMed, China National Knowledge Infrastructure, Embase, Medline, and Google Scholar to elaborate on the mechanism and complications of COVID-19 cytokine storm, therapeutic interventions, and the way forward to discovering effective biocompatible drug targets.

22 November 2025 in ACS Chemical Biology
Verified
Journal Article
Closed access
Augustine MaduekeAugustine Madueke
Augustine Madueke
RARafael Andrade
Rafael Andrade
MPMary Kay H. Pflum
Mary Kay H. Pflum